Samsung Bioepis acquires approval of ‘Brenzys’ in Canada
Samsung Bioepis weighed anchor to enter the U.S. market with its first self-developed biosimilar.
On the 12th, Samsung Bioepis(CEO Han-Seung Ko) announced it acquired sale approval of the Enbrel(etanercept) biosimilar Brenzys(SB4, European name: Benepali) in Canada on the 31st of the last month....
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
